FGF19 Is Coamplified With CCND1 to Promote Proliferation in Lung Squamous Cell Carcinoma and Their Combined Inhibition Shows Improved Efficacy

Yanshuang Zhang, Tingyu Wu, Fan Li, Yirui Cheng, Qing Han, Xin Lü, Shun Lü, Weiliang XiaFrontiers in Oncology 2022 · DOI

Abstract

Lung squamous cell carcinoma (LUSC) remains as a major cause of cancer-associated mortality with few therapeutic options. Continued research on new driver genes is particularly important. FGF19, a fibroblast growth factor, is frequently observed as amplified in human LUSC, which is also associated with multiple genomic gains and losses. However, the importance of these associated changes is largely unknown. In this study, we aimed to clarify a novel mechanism that link neighboring oncogene co-amplification in the development of LUSC. We found that FGF19 was co-amplified and co-expressed with its neighboring gene CCND1 in a subset of LUSC patients and associated with poor prognosis. Moreover, FGF19 combined with CCND1 promoted the cell cycle progression of LUSC cells. Mechanistically, FGF19 also enhanced CCND1 expression by activating FGFR4-ERK1/2 signaling and strengthening CCND1-induced phosphorylation and inactivation of retinoblastoma (RB). In a murine model of lung orthotopic cancer, knockdown of CCND1 was found to prolong survival by attenuating FGF19-induced cell proliferation. Furthermore, the combination treatment of the FGFR4 inhibitor BLU9931 and the CDK4/6 inhibitor palbociclib potentiated the growth inhibition and arrested cells in G1 phase. In vivo, co-targeting FGFR4 and CDK4/6 also showed marked inhibition of tumor growth than single agent treatment. These findings further elucidate the oncogenic role of FGF19 in LUSC and provide insights into how the co-amplification of neighboring genes synergistically function to promote cancer growth, and combined inhibition against both FGF19 and CCND1 is more effective.

Introduction

Lung squamous cell carcinoma (LUSC) is a leading cause of cancer-related deaths globally, yet it lacks the diverse targeted therapy options available for other subtypes like adenocarcinoma. Genomic research has identified large amplicons in LUSC, particularly in the 11q13.3 chromosomal region, which contains potential oncogenic drivers. This study investigates the cooperative relationship between two neighboring genes in this region: the growth factor FGF19 and the cell-cycle regulator CCND1 (Cyclin D1). The researchers sought to determine if these genes act as a synergistic unit to drive tumor proliferation and whether this axis can be therapeutically targeted.

Genomic Landscape and Co-amplification

By analyzing high-profile genomic databases such as TCGA, Oncomine, and cBioPortal, the research team discovered that FGF19 and CCND1 are co-amplified in approximately 12-14% of LUSC patients. This co-occurrence is strongly linked to poor patient prognosis and reduced progression-free survival. The study utilized several LUSC cell lines (H520, SK-MES-1, HCC95) to validate these findings, performing both gain-of-function and loss-of-function experiments to observe the impact on cell viability.

Comprehensive genomic analysis showing co-amplification and co-expression of FGF19 and CCND1 in LUSC cohorts.

The FGF19-CCND1 Feed-Forward Mechanism

A primary finding of the study is that FGF19 does not merely coexist with CCND1; it actively drives its expression. FGF19 binds to the FGFR4 receptor, triggering the ERK1/2 signaling pathway, which in turn upregulates CCND1. This creates a potent "feed-forward" loop that accelerates the cell cycle. Both genes ultimately converge on the Retinoblastoma (RB) protein, where CCND1/CDK4/6 complexes phosphorylate and inactivate RB, removing a critical brake on cell division.

Correlation analysis between FGF19 and CCND1 mRNA expression in the TCGA LUSC cohort.

Therapeutic Synergy and In Vivo Efficacy

The researchers tested the combination of BLU9931 (an FGFR4 inhibitor) and Palbociclib (a CDK4/6 inhibitor). In cell viability assays, the dual treatment showed true synergy (Combination Index < 1), causing massive G1 phase arrest and pushing cells into cellular senescence. These results were mirrored in an orthotopic lung cancer mouse model, where the combination therapy significantly reduced tumor bioluminescence and prolonged survival compared to single-agent treatments.

Conclusion

This research identifies the FGF19-CCND1 axis as a critical driver in a subset of LUSC patients. While clinical translation will require further study into other neighboring genes and potential resistance mechanisms, the findings provide a strong rationale for dual-targeting strategies in LUSC patients harboring 11q13.3 amplicons.

Summary updated

Abstract

Lung squamous cell carcinoma (LUSC) remains as a major cause of cancer-associated mortality with few therapeutic options. Continued research on new driver genes is particularly important. FGF19, a fibroblast growth factor, is frequently observed as amplified in human LUSC, which is also associated with multiple genomic gains and losses. However, the importance of these associated changes is largely unknown. In this study, we aimed to clarify a novel mechanism that link neighboring oncogene co-amplification in the development of LUSC. We found that FGF19 was co-amplified and co-expressed with its neighboring gene CCND1 in a subset of LUSC patients and associated with poor prognosis. Moreover, FGF19 combined with CCND1 promoted the cell cycle progression of LUSC cells. Mechanistically, FGF19 also enhanced CCND1 expression by activating FGFR4-ERK1/2 signaling and strengthening CCND1-induced phosphorylation and inactivation of retinoblastoma (RB). In a murine model of lung orthotopic cancer, knockdown of CCND1 was found to prolong survival by attenuating FGF19-induced cell proliferation. Furthermore, the combination treatment of the FGFR4 inhibitor BLU9931 and the CDK4/6 inhibitor palbociclib potentiated the growth inhibition and arrested cells in G1 phase. <i>In vivo</i>, co-targeting FGFR4 and CDK4/6 also showed marked inhibition of tumor growth than single agent treatment. These findings further elucidate the oncogenic role of FGF19 in LUSC and provide insights into how the co-amplification of neighboring genes synergistically function to promote cancer growth, and combined inhibition against both FGF19 and CCND1 is more effective.
BibTeX
@inproceedings{zhang2022fgf,
  author = {Yanshuang Zhang and Tingyu Wu and Fan Li and Yirui Cheng and Qing Han and Xin Lü and Shun Lü and Weiliang Xia},
  title = {{FGF19 Is Coamplified With CCND1 to Promote Proliferation in Lung Squamous Cell Carcinoma and Their Combined Inhibition Shows Improved Efficacy}},
  booktitle = {Frontiers in Oncology},
  year = {2022},
  doi = {10.3389/fonc.2022.846744},
}
Figure